Trial · NCT05883085
A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL
NCT05883085, Phase 2, Unknown, Peking Union Medical College Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL. Trials, record NCT05883085. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05883085
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL
- NCT number
- NCT05883085
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Peking Union Medical College Hospital
- Conditions
- Pheochromocytoma, Paraganglioma
- Interventions
- Anlotinib hydrochloride
- First posted
- 2023-05-31
- Last updated
- 2023-05-31
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The proportion of PPGL patients whose tumor change from unresectable to resectable tumor. | At the end of Cycle 4 (each cycle is 21 days) | The proportion of PPGL patients whose tumor change from unresectable to resectable |
| Secondary | The objective response rate (ORR) | At the end of Cycle 4 (each cycle is 21 days) | Determined by the RECIST 1.1 criteria |
| Secondary | The ratio of tumor shrinkage | At the end of Cycle 4 (each cycle is 21 days) | The proportion of decrease in the sum of total size of the target lesions after treatment compared to before treatment. |
| Secondary | The biochemical response. | At the end of Cycle 4 (each cycle is 21 days) | An effective response of 24hCA, MNs meant that the concentration decreaseed by more than 40% than the baseline value or decreaseed to the normal range. |
| Secondary | R0 resection rate. | At the end of Cycle 4 (each cycle is 21 days) | The proportion of patients with surgical resection reached R0 resection |
| Secondary | Major pathological response rate (MPR). | At the end of Cycle 4 (each cycle is 21 days) | Defined as the remaining surviving tumor after surgical resection do not exceed 10% of the initial tumor tissue. |
| Secondary | Pathologic complete remission (pCR). | At the end of Cycle 4 (each cycle is 21 days) | There is no tumor cells microscopically. |
| Secondary | Safety of anlotinib treatment. | At the end of Cycle 1 (each cycle is 21 days) | Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05883085
GET https://conductscience.org/api/trials/v1/NCT05883085/registered